{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:39:53Z","timestamp":1793911193868,"version":"4.8.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["20200402RINA"],"award-info":[{"award-number":["20200402RINA"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jgar.2023.10.012","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T22:07:08Z","timestamp":1698876428000},"page":"426-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir\/emtricitabine\/tenofovir alafenamide"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0524-3434","authenticated-orcid":false,"given":"Jen-Yu","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-7721","authenticated-orcid":false,"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ching","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-0836","authenticated-orcid":false,"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2023.10.012_bib0001","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 2021. Available at: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. [accessed 16.08.2022]."},{"key":"10.1016\/j.jgar.2023.10.012_bib0002","unstructured":"European AIDS Clinical Society. EACS guidelines version 11.0. 2021. Available at: https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf. [accessed 16.08.2022]."},{"key":"10.1016\/j.jgar.2023.10.012_bib0003","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. Available at: https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1357089\/retrieve. [accessed 16.08.2022]."},{"key":"10.1016\/j.jgar.2023.10.012_bib0004","unstructured":"Gilead Sciences, Inc. Full prescribing information: BIKTARVY, bictegravir, emtricitabine, and tenofovir alafenamide, oral tablets. 2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210251s000lbl.pdf. [accessed 16.08.2022]."},{"key":"10.1016\/j.jgar.2023.10.012_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2023.10.012_bib0006","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.10.012_bib0007","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.10.012_bib0008","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study","volume":"88","author":"Hagins","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2023.10.012_bib0009","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2023.10.012_bib0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12879-017-2626-z","article-title":"Cardiovascular risk and dyslipidemia among persons living with HIV: a review","volume":"17","author":"Maggi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2023.10.012_bib0011","series-title":"Endotext. South","article-title":"Lipid disorders in people with HIV","author":"Sarkar","year":"2000"},{"key":"10.1016\/j.jgar.2023.10.012_bib0012","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2023.10.012_bib0013","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2023.10.012_bib0014","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial","volume":"82","author":"Kityo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2023.10.012_bib0015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2023.10.012_bib0016","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/QAD.0000000000002930","article-title":"Implications of weight gain with newer anti-retrovirals:10-year predictions of cardiovascular disease and diabetes","volume":"35","author":"McCann","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2023.10.012_bib0017","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2019.12.029","article-title":"Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","volume":"92","author":"Kuo","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2023.10.012_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2021.07.030","article-title":"Long-term weight gain after initiating combination antiretroviral therapy in treatment-na\u00efve Asian people living with human immunodeficiency virus","volume":"110","author":"Ando","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2023.10.012_bib0019","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/QAI.0000000000002650","article-title":"Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV","volume":"87","author":"Huang","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2023.10.012_bib0020","doi-asserted-by":"crossref","first-page":"ofab542","DOI":"10.1093\/ofid\/ofab542","article-title":"Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter?","volume":"8","author":"Wood","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.10.012_bib0021","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s12889-022-12762-4","article-title":"Birth cohort, sex and educational disparities in the trajectories of body mass index in Taiwan: a longitudinal study","volume":"22","author":"Wong","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jgar.2023.10.012_bib0022","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/03007995.2021.2007006","article-title":"Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide or bictegravir\/emtricitabine\/tenofovir alafenamide in the United States","volume":"38","author":"Emond","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jgar.2023.10.012_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081823","article-title":"Viro-immunological, clinical outcomes and costs of switching to BIC\/TAF\/FTC in a cohort of people living with HIV: a 48-week prospective analysis","volume":"10","author":"Mazzitelli","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jgar.2023.10.012_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565\u2009years of age","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2023.10.012_bib0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/v14010122","article-title":"Impact of combined antiretroviral therapy on metabolic syndrome components in adult people living with HIV: a literature review","volume":"14","author":"Sapu\u0142a","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jgar.2023.10.012_bib0026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.metabol.2018.11.005","article-title":"Obesity and dyslipidemia","volume":"92","author":"Vekic","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.jgar.2023.10.012_bib0027","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","article-title":"Global epidemiology of dyslipidaemias","volume":"18","author":"Pirillo","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jgar.2023.10.012_bib0028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jgar.2023.10.012_bib0029","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/EDE.0000000000000815","article-title":"Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis","volume":"29","author":"Nansseu","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.jgar.2023.10.012_bib0030","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/cells11111841","article-title":"Inhibition of adipose tissue beiging by HIV integrase inhibitors, dolutegravir and bictegravir, is associated with adipocyte hypertrophy, hypoxia, elevated fibrosis, and insulin resistance in simian adipose tissue and human adipocytes","volume":"11","author":"Ngono Ayissi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jgar.2023.10.012_bib0031","doi-asserted-by":"crossref","first-page":"ofab077","DOI":"10.1093\/ofid\/ofab077","article-title":"Reeds D, O\u2019Halloran JA. Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus","volume":"8","author":"Nolan","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.10.012_bib0032","doi-asserted-by":"crossref","first-page":"96","DOI":"10.17925\/EE.2022.18.2.96","article-title":"Assessing the incidence of new-onset diabetes mellitus with statin use: a systematic review of the systematic reviews and meta-analyses","volume":"18","author":"Singh","year":"2022","journal-title":"touchREV Endocrinol"},{"key":"10.1016\/j.jgar.2023.10.012_bib0033","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAI.0000000000003083","article-title":"Statins utilization in adults with HIV: the treatment gap and predictors of statin initiation","volume":"91","author":"Coburn","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2023.10.012_bib0034","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.amjcard.2015.03.025","article-title":"DM Lloyd-Jones. A systematic review of the usefulness of statin therapy in HIV-infected patients","volume":"115","author":"Feinstein","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jgar.2023.10.012_bib0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jmii.2021.04.004","article-title":"Participation in cancer screening among people living with HIV at a university hospital","volume":"55","author":"Wu","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2023.10.012_bib0036","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1056\/NEJMoa1014296","article-title":"Changes in diet and lifestyle and long-term weight gain in women and men","volume":"364","author":"Mozaffarian","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2023.10.012_bib0037","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(03)14234-1","volume":"362","author":"Durrington","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2023.10.012_bib0038","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41588-020-0637-y","article-title":"Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis","volume":"52","author":"Vujkovic","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jgar.2023.10.012_bib0039","first-page":"34","article-title":"Unintentional weight loss in older adults","volume":"104","author":"Gaddey","year":"2021","journal-title":"Am Fam Physician"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523001819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523001819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T21:48:52Z","timestamp":1712699332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523001819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":39,"alternative-id":["S2213716523001819"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.10.012","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir\/emtricitabine\/tenofovir alafenamide","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}